top of page

Mesothelioma UK

September 21, 2022

Mesothelioma Matters UK highlighted RS Oncology in their Autumn Newsletter.

15% of cancer patients

develop pleural effusion as their

disease spreads to the lungs and accumulates excess fluid. This condition is common among mesothelioma patients. Earlier this year, RS Oncology, LLC, a US-based biotechnical company focused on the treatment of patients with malignant

pleural effusion (MPE) and mesothelioma,

initiated its MITOPE clinical trial, a

first-in-human Phase 1/2 clinical trial

in the UK.

91 views0 comments

Recent Posts

See All
bottom of page